Polypharmacy in elderly people: epidemiology, consequences and prevention strategies

Main Article Content

Eirini Kotsalou

Abstract

Aging is a status often associated with multiple comorbidities which require pharmacologic intervention and complex medication regimens. Aging population results to the increase of chronic diseases and subsequent comorbidities that require concomitant multiple medications. It is reported that about 80 % of elderly have at least one chronic condition, and about half of them have at least two (such as heart disease, hypertension, diabetes mellitus, arthritis, and cancer). According the literature the worldwide polypharmacy prevalence has a wide range (between 5 to 78 %) due to different definitions on the number of medications taken (ranging between 2 and 9) and the different samples studied. In most studies polypharmacy was more common between women and in more elderly people. Many multicenter studies have been performed to define the term of polypharmacy and its prevalence in the elderly population. Polypharmacy is of growing concern for the older adults, because it can be very dangerous for this population due to altered absorption, distribution, metabolism and excretion of the drugs within their body reflecting unexpected pharmacokinetics and pharmacodynamics of various medications. This fact can lead to adverse drug reactions (ADR), drug interactions, noncompliance and reduced adherence, reduced functional status, geriatric syndromes, high risk of hospitalization and possible death. Over the last decade, there are several evaluation tools which can help the General Practitioner prevent the polypharmacy in the elderly. As prescribing for this group of individuals is a very challenging procedure, the General Practitioner should balance between under-treatment, over-treatment and risks and benefits. This review concluded that we need more cross-sectional clinical studies on practical preventive interventions to be applied not only on the population which is already exposed to polypharmacy, but also to the general population.

Article Details

How to Cite
Kotsalou, E. “Polypharmacy in Elderly People: Epidemiology, Consequences and Prevention Strategies”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 17, no. 1, Apr. 2021, pp. 56-62, doi:10.22141/2224-0721.17.1.2021.226432.
Section
Literature Review

References

Al-Dahshan A, Al-Kubiasi N, Al-Zaidan M, Saeed W, Kehyayan V, Bougmiza I. Prevalence of polypharmacy and the association with non-communicable diseases in Qatari elderly patients attending primary healthcare centers: A cross-sectional study. PLoS One. 2020 Jun 11;15(6):e0234386. doi:10.1371/journal.pone.0234386.

Alwhaibi M, Balkhi B, Alhawassi TM, et al. Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open. 2018 May 24;8(5):e020852. doi:10.1136/bmjopen-2017-020852.

van Vugt S, Aarts G, Lamfers E, et al. Comorbidity Differentiation and Risk Stratification in the Elderly Patient with Polypharmacy: A Prospective Primary Care Registry on Oral Anticoagulation Therapy. Eur Cardiol. 2020 May 15;15:e46. doi:10.15420/ecr.2020.15.1.PO23.

Pereira KG, Peres MA, Iop D, et al. Polypharmacy among the elderly: a population-based study. Rev Bras Epidemiol. 2017 Apr-Jun;20(2):335-344. Portuguese, English. doi:10.1590/1980-5497201700020013.

Mortazavi SS, Shati M, Keshtkar A, Malakouti SK, Bazargan M, Assari S. Defining polypharmacy in the elderly: a systematic review protocol. BMJ Open. 2016 Mar 24;6(3):e010989. doi:10.1136/bmjopen-2015-010989.

Carmona-Torres JM, Cobo-Cuenca AI, Recio-Andrade B, Laredo-Aguilera JA, Martins MM, Rodríguez-Borrego MA. Prevalence and factors associated with polypharmacy in the older people: 2006-2014. J Clin Nurs. 2018 Aug;27(15-16):2942-2952. doi:10.1111/jocn.14371.

Slater N, White S, Venables R, Frisher M. Factors associated with polypharmacy in primary care: a cross-sectional analysis of data from The English Longitudinal Study of Ageing (ELSA). BMJ Open. 2018 Mar 14;8(3):e020270. doi:10.1136/bmjopen-2017-020270.

Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011 May;67(5):507-519. doi:10.1007/s00228-010-0977-0.

Schuler J, Dückelmann C, Beindl W, Prinz E, Michalski T, Pichler M. Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria. Wien Klin Wochenschr. 2008;120(23-24):733-741. doi:10.1007/s00508-008-1089-z.

Dwyer LL, Han B, Woodwell DA, Rechtsteiner EA. Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. Am J Geriatr Pharmacother. 2010 Feb;8(1):63-72. doi:10.1016/j.amjopharm.2010.01.001.

Morin L, Johnell K, Laroche ML, Fastbom J, Wastesson JW. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018 Mar 12;10:289-298. doi:10.2147/CLEP.S153458.

Kim HA, Shin JY, Kim MH, Park BJ. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One. 2014 Jun 10;9(6):e98043. doi:10.1371/journal.pone.0098043.

Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci. 2015 Aug;70(8):989-995. doi:10.1093/gerona/glv013.

Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Oct 10;17(1):230. doi:10.1186/s12877-017-0621-2.

Díez-Manglano J, Giménez-López M, Garcés-Horna V, et al. Excessive polypharmacy and survival in polypathological patients. Eur J Clin Pharmacol. 2015 Jun;71(6):733-739. doi:10.1007/s00228-015-1837-8.

Lavan AH, Gallagher PF, O'Mahony D. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging. 2016 Jun 23;11:857-866. doi:10.2147/CIA.S80280.

Jódar-Sánchez F, Malet-Larrea A, Martín JJ, et al. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program. Pharmacoeconomics. 2015 Jun;33(6):599-610. doi:10.1007/s40273-015-0270-2.

Pedrós C, Formiga F, Corbella X, Arnau JM. Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features. Eur J Clin Pharmacol. 2016 Feb;72(2):219-226. doi:10.1007/s00228-015-1974-0.

Koronkowski M, Eisenhower C, Marcum Z. An Update on Geriatric Medication Safety and Challenges Specific to the Care of Older Adults. Ann Longterm Care. 2016 Mar;24(3):37-40.

Yang M, Lu J, Hao Q, Luo L, Dong B. Does residing in urban or rural areas affect the incidence of polypharmacy among older adults in western China? Arch Gerontol Geriatr. 2015 Mar-Apr;60(2):328-333. doi:10.1016/j.archger.2014.11.004.

Nguyen OK, Chan CV, Makam A, Stieglitz H, Amarasingham R. Envisioning a social-health information exchange as a platform to support a patient-centered medical neighborhood: a feasibility study. J Gen Intern Med. 2015 Jan;30(1):60-67. doi:10.1007/s11606-014-2969-8.

Jensen LD, Andersen O, Hallin M, Petersen J. Potentially inappropriate medication related to weakness in older acute medical patients. Int J Clin Pharm. 2014 Jun;36(3):570-580. doi:10.1007/s11096-014-9940-y.

Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015 May 1;33(13):1453-1459. doi:10.1200/JCO.2014.58.7550.

Narayan SW, Nishtala PS. Associations of Potentially Inappropriate Medicine Use with Fall-Related Hospitalisations and Primary Care Visits in Older New Zealanders: A Population-Level Study Using the Updated 2012 Beers Criteria. Drugs Real World Outcomes. 2015 Jun;2(2):137-141. doi:10.1007/s40801-015-0020-y.

Kann IC, Lundqvist C, Lurås H. Polypharmacy Among the Elderly in a List-Patient System. Drugs Real World Outcomes. 2015 Sep;2(3):193-198. doi:10.1007/s40801-015-0036-3.

Cadogan C, Ryan C, Gormley G, et al. Dispensing appropriate polypharmacy to older people in primary care: a qualitative, theory-based study of community pharmacists' perceptions and experiences. Int J Pharm Pract. 2015;23(Ігщщд 2):32. doi:10.1111/ijpp.12213.

Cadogan CA, Ryan C, Hughes CM. Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many. Drug Saf. 2016 Feb;39(2):109-116. doi:10.1007/s40264-015-0378-5.

Steinman MA. Polypharmacy-Time to Get Beyond Numbers. JAMA Intern Med. 2016 Apr;176(4):482-483. doi:10.1001/jamainternmed.2015.8597.

Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015 May;175(5):827-834. doi:10.1001/jamainternmed.2015.0324.

Hu T, Dattani ND, Cox KA, et al. Effect of comorbidities and medications on frequency of primary care visits among older patients. Can Fam Physician. 2017 Jan;63(1):45-50.

Al-Hashar A, Al Sinawi H, Al Mahrizi A, Al-Hatrushi M. Prevalence and Covariates of Polypharmacy in Elderly Patients on Discharge from a Tertiary

Badawy NA, Labeeb SA, Alsamdan MF, Alazemi BF. Prevalence and Risk of Polypharmacy among Community-Dwelling, Elderly Kuwaiti Patients. Med Princ Pract. 2020;29(2):166-173. doi:10.1159/000503298.

Alsuwaidan A, Almedlej N, Alsabti S, et al. A Comprehensive Overview of Polypharmacy in Elderly Patients in Saudi Arabia. Geriatrics (Basel). 2019 May 15;4(2):36. doi:10.3390/geriatrics4020036.

Kim LD, Koncilja K, Nielsen C. Medication management in older adults. Cleve Clin J Med. 2018 Feb;85(2):129-135. doi:10.3949/ccjm.85a.16109.

Payne RA. The epidemiology of polypharmacy. Clin Med (Lond). 2016 Oct;16(5):465-469. doi:10.7861/clinmedicine.16-5-465.

Alvis BD, Hughes CG. Physiology Considerations in Geriatric Patients. Anesthesiol Clin. 2015 Sep;33(3):447-456. doi:10.1016/j.anclin.2015.05.003.

Flanagan N, Beizer J. Medication Reconciliation and Education for Older Adults: Using the 2015 AGS Beers Criteria as a Guide. Home Healthc Now. 2016 Nov/Dec;34(10):542-549. doi:10.1097/NHH.0000000000000469.

By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015 Nov;63(11):2227-2246. doi:10.1111/jgs.13702.

Salbu RL, Feuer J. A Closer Look at the 2015 Beers Criteria. J Pharm Pract. 2017 Aug;30(4):419-424. doi:10.1177/0897190016663072.

Rawle MJ, Cooper R, Kuh D, Richards M. Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study. J Am Geriatr Soc. 2018 May;66(5):916-923. doi:10.1111/jgs.15317.

Davies EA, O'Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol. 2015 Oct;80(4):796-807. doi:10.1111/bcp.12596.

Turgeon J, Michaud V, Steffen L. The Dangers of Polypharmacy in Elderly Patients. JAMA Intern Med. 2017 Oct 1;177(10):1544. doi:10.1001/jamainternmed.2017.4790.